Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (2367)	10/17/1997 8:52:00 AM
From: Peter Silsbee	of 6136

Not sure what you mean by the two populations of patients. Resistant strains are somewhat dependent on numbers required. I suspect that most patients have a few copies of resistant virus, but its emergence is dependent one many factors, many of which are host dependent. Sounds like you do understand what I meant, but disagree with me. I suspected that this might be a weak point in the model. Do others on this thread with medical knowledge agree with Henry that "most patients have a few copies of resistant virus?" If so, what prevents those few copies from quickly becoming lots and lots of copies? The other drugs in the cocktail? I think it still may be a useful simplification, when trying to model failure rates, to consider these two populations. My point was that PIs would ... not represent ... a "cure" ... No argument here. PLS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next